The Inhibrx pickup gives Sanofi access to INBRX-101, a human recombinant protein that is being investigated in patients with a rare disease known as alpha-1 antitrypsin deficiency.
Sanofi is acquiring Inhibrx to get its hands on a drug candidate in pivotal testing for the protein deficiency alpha-1 antitrypsin deficiency, which leads to lung and liver problems. Inhibrx’s remaining assets will be spun out into a new company.
Press Release: Sanofi Pipeline Transformation to Accelerate globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Sanofi says it has 12 blockbusters in its back pocket. Will investors believe it? NEW YORK The top executives at French drug giant Sanofi on Wednesday…